CytoMed Therapeutics Limited (GDTC) AI Stock Analysis

• Market Cap: $21.70M
• Dividend Yield: N/A
• Average Volume (3M): 15.60K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.16
• Revenue Growth: N/A
• EPS Growth: 38.80%
• Country: US
• Employees: 43
• Sector: Healthcare
• Sector Strength: 47
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 11,733,712
• 10 Day Avg. Volume: 10,968
• 30 Day Avg. Volume: 15,595
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.66
• Enterprise Value/Revenue: 686.62
• Enterprise Value/Gross Profit: -290.53
• Enterprise Value/Ebitda: -20.45
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 41 Neutral
• Price Target: ―

CytoMed Therapeutics Limited is facing significant financial challenges, with substantial declines in revenue and persistent losses. The technical indicators suggest a bearish trend with potential short-term opportunities due to oversold conditions. Valuation metrics, including a negative P/E ratio, reflect poor profitability and lack of dividend yield. These factors contribute to a low overall stock score, highlighting the need for improved financial strategies and market conditions to enhance investor confidence.

CytoMed Therapeutics Limited Business Overview & Revenue Model

Company Description

CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers. The company's lead product candidate is CTM-N2D, which consists of expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. It is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells, and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. The company was incorporated in 2018 and is headquartered in Singapore.

How the Company Makes Money

CytoMed Therapeutics Limited generates revenue through the development and commercialization of its cell therapy products. The company invests in research and development to advance its pipeline of therapeutic candidates, which, once approved, are marketed and sold to healthcare providers and institutions. Revenue streams include product sales, potential licensing agreements, and strategic partnerships with larger pharmaceutical companies, which may involve upfront payments, milestone payments, and royalties. The company's financial success is contingent upon the successful approval and commercialization of its therapeutic candidates, as well as the establishment of collaborations with industry partners to enhance market reach and adoption.

CytoMed Therapeutics Limited Financial Statement Overview

Summary

Overall, CytoMed Therapeutics Limited faces significant financial hurdles, characterized by declining revenues, persistent losses, and cash flow deficits. Despite maintaining a strong equity position relative to debt, the company needs to address its cash management and revenue generation strategies to improve its financial health and stability.

Income Statement

The income statement reveals significant challenges, with the company experiencing a decline in total revenue from $290,560 in 2023 to $52,005 in 2024, indicating a negative revenue growth rate. Additionally, the net income remained negative, with a considerable net loss of $1,883,178 in 2024, reflecting poor profitability and a concerning net profit margin.

Balance Sheet

The balance sheet shows a strong equity position with stockholders' equity significantly outweighing total debt, resulting in a low debt-to-equity ratio. However, the reduction in total assets and stockholders' equity from 2023 to 2024 highlights potential risks and financial instability.

Cash Flow

The cash flow statement indicates negative operating cash flow, with a substantial free cash flow deficit of $2,742,350 in 2024. While the company had a significant capital expenditure in 2024, the free cash flow remains negative, pointing to cash management challenges and the need for more efficient cash utilization.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	52.01K	290.56K	―	―	―
Gross Profit	-515.82K	213.09K	―	―	―
EBITDA	-1.79M	-2.94M	―	―	―
Net Income	-1.88M	-3.13M	―	―	―
Balance Sheet
Total Assets	7.38M	12.37M	―	―	―
Cash, Cash Equivalents and Short-Term Investments	3.64M	9.00M	―	―	―
Total Debt	463.25K	448.02K	―	―	―
Total Liabilities	750.59K	1.12M	―	―	―
Stockholders Equity	6.57M	8.49M	―	―	―
Cash Flow
Free Cash Flow	-2.74M	―	―	―	―
Operating Cash Flow	-1.69M	-2.60M	―	―	―
Investing Cash Flow	494.59K	―	―	―	―
Financing Cash Flow	-33.36K	8.27M	―	―	―

CytoMed Therapeutics Limited Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GDTC, the sentiment is Neutral. The current price of 1.85 is above the 20-day moving average (MA) of 1.82, below the 50-day MA of 2.02, and below the 200-day MA of 2.37, indicating a neutral trend. The MACD of -0.06 indicates Negative momentum. The RSI at 47.81 is Neutral, neither overbought nor oversold. The STOCH value of 68.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GDTC.

CytoMed Therapeutics Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLNN	54 Neutral	$56.55M	―	-1738.36%	―	-35.29%	45.18%
Sector *	51 Neutral	$7.88B	-0.12	-39.86%	2.18%	21.38%	-1.56%
BRNS	46 Neutral	$47.61M	―	-53.78%	―	―	-5.42%
GDTC	41 Neutral	$21.70M	―	-24.97%	―	―	38.80%
PYPD	41 Neutral	$35.46M	―	-312.77%	―	―	61.18%
VYNE	40 Underperform	$8.51M	―	-67.73%	―	-2.06%	64.86%
TPST	39 Underperform	$44.51M	―	-322.57%	―	―	3.39%